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A change in the serum creatinine is not sensitive for an early
diagnosis of acute kidney injury. We evaluated urinary levels
of matrix metalloproteinase-9 (MMP-9), N-acetyl-b-D-
glucosaminidase (NAG), and kidney injury molecule-1 (KIM-1)
as biomarkers for the detection of acute kidney injury. Urine
samples were collected from 44 patients with various acute
and chronic kidney diseases, and from 30 normal subjects in
a cross-sectional study. A case–control study of children
undergoing cardio-pulmonary bypass surgery included urine
specimens from each of 20 patients without and with acute
kidney injury. Injury was defined as a greater than 50%
increase in the serum creatinine within the first 48 h after
surgery. The biomarkers were normalized to the urinary
creatinine concentration at 12, 24, and 36 h after surgery with
the areas under the receiver-operating characteristic curve
compared for performance. In the cross-sectional study, the
area under the curve for MMP-9 was least sensitive followed
by KIM-1 and NAG. Combining all three biomarkers achieved
a perfect score diagnosing acute kidney injury. In the
case–control study, KIM-1 was better than NAG at all time
points, but combining both was no better than KIM-1 alone.
Urinary MMP-9 was not a sensitive marker in the case–control
study. Our results suggest that urinary biomarkers allow
diagnosis of acute kidney injury earlier than a rise in serum
creatinine.
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The absence of sensitive and specific biomarkers for the early
detection of acute kidney injury (AKI) has impaired progress
in the diagnosis and treatment of patients with AKI and has
had a detrimental effect on the design and possibly the
outcomes of clinical trials of AKI. Traditional blood
(creatinine, blood urea nitrogen) and urinary markers of
kidney injury (urinary casts, fractional excretion of Naþ ) are
insensitive for the early diagnosis of AKI.1 AKI is a
heterogeneous entity associated with various clinical pre-
sentations, treatments, and procedures, and is often seen in
the setting of multiple organ failure and sepsis. Many
potential therapeutic agents have been tried but with little
success. Absence of reliable biomarkers for early detection of
injury leads to delay in the introduction of treatment until
well into the course of the renal disease. It is possible that a
single biomarker will be insufficiently sensitive and specific
across the full spectrum of AKI. A panel of biomarkers may
be required to optimize the early detection of AKI.
Recently, several protein biomarkers have been evaluated
as non-invasive indicators of kidney injury.2 Human kidney
injury molecule-1 (KIM-1) is a type 1 transmembrane
protein that is not detectable in normal kidney tissue or
urine, but is expressed at very high levels in dedifferentiated
proximal tubule epithelial cells in human and rodent kidneys
after ischemic or toxic injury and in renal cell carcinoma.3–7
We previously reported that a soluble form of cleaved KIM-1
can be detected in the urine of patients with AKI and
that KIM-1 is a sensitive urinary biomarker for AKI.4
High urinary KIM-1 expression was also associated with
adverse clinical outcomes in patients with AKI.8 N-acetyl-b-
D-glucosaminidase (NAG) is a lysosomal enzyme found mainly
in proximal tubular cells that has been shown to be a
sensitive proximal tubular injury marker in the setting of a
wide variety of drugs, environmental toxicants, contrast-
induced toxicity, and ischemic acute tubular injury.9–12 Matrix
metalloproteinase-9 (MMP-9) is elevated in postischemic
kidney tissue in an animal model.13 MMP-9 has not previously
been evaluated as a urinary biomarker for AKI. It has
been found in disulfide-linked complexes with neutrophil
gelatinase-associated lipocalin,14 which has been implicated
as an early predictive urinary biomarker of ischemic AKI in
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pediatric and adult patients after cardiac surgery.15,16 We
hypothesized that urine samples from patients with AKI might
also contain elevated levels of MMP-9. In this study, we
examined the diagnostic utility of urinary MMP-9, NAG, and
KIM-1 as biomarkers, singly or in combination, for the
detection of AKI in a cross-sectional study in adults and
the temporal expression pattern of urinary biomarkers before
the development of AKI in a prospective case–control study
in children.
RESULTS
Cross-sectional study
Characteristics of patients with AKI. Clinical characteristics
of all patients from whom urine was evaluated for the
presence of urinary biomarkers are reported in Table 1.
Patients with AKI due to ischemia in the setting of sepsis and
hypoperfusion (n¼ 24)/or nephrotoxins (n¼ 1) and con-
trast-induced nephropathy (n¼ 4) were diagnosed based
on evidence for tubular cell injury including muddy-brown
or granular casts in urine sediments, clinical history, and
elevation of serum creatinine. In 12 patients, ischemia was
associated with sepsis and in nine other patients, cardiac
arrest and cardiogenic shock accompanied myocardium
infarctions or various cardiovalvular operations. In the
remaining two patients, ischemia developed in the setting
of massive hepatic artery bleeding and trauma. One patient
developed AKI in the setting of rhabdomyolysis. Eleven of 29
patients required renal replacement therapy. Eight patients
with AKI died in hospital. Each patient with contrast-
induced nephropathy had (1) exposure to contrast dye with a
well-documented elevation of serum creatinine and blood
urea nitrogen temporally related to the contrast dye exposure,
and (2) rapidly reversible AKI.
Quantitation of human urinary MMP-9, NAG, and KIM-1
proteins. Comparison of median normalized biomarker
levels among patients with AKI, control, or urinary tract
infection (UTI) in the cross-sectional study is shown in
Table 2. Patients with AKI had higher levels of KIM-1
(Po0.001), NAG (Po0.001), and MMP-9 (Po0.001) than
control subjects. KIM-1 and NAG levels were higher in
patients with AKI than in patients with UTI (P¼ 0.002,
Po0.001, respectively). In contrast, MMP-9 levels were
higher in those with UTI (Po0.001). Normalized levels of
urinary MMP-9, NAG, and KIM-1 are shown in combined
box and whisker and dot plot in Figure 1.
Receiver-operating characteristic curves analysis. The per-
formance of each biomarker in differentiating patients with
AKI from control group is illustrated by receiver-operating
characteristic curves (ROC) curves in Figure 2. The areas
under the curve (AUCs) and 95% confidence interval for the
diagnosis of AKI using normalized MMP-9, NAG, KIM-1, as
well as the combination of all three biomarkers, were 0.74
(0.63, 0.83), 0.97 (0.91, 1.00), 0.90 (0.81, 0.96), and 1.00
(0.98, 1.00), respectively. Comparisons of AUCs between each
pair of biomarkers was as follows: KIM-1 vs NAG, P¼ 0.08;
KIM-1 vs MMP-9, P¼ 0.03; and NAG vs MMP-9, Po0.001.
Urinary NAG and KIM-1 had the best diagnostic perfor-
mances for detecting AKI in the cross-sectional study.
Case–control study
Patient characteristics. The clinical and demographic char-
acteristics of 40 pediatric patients from whom urine was
evaluated for the presence of urinary biomarkers are reported
in Table 3. AKI was diagnosed in eight of 20 patients between
24 and 48 h following cardiopulmonary bypass (CPB), and
between 48 and 72 h in the remaining 12 patients. No
Table 1 | Baseline characteristics of patients with renal diseases and control in cross-sectional study
Control (n=45)
Characteristic AKI (n=29) Normal (n=30) CKD (n=15) UTI (n=10)
Age (years) 59.0±3.6 40.8±2.4 69.2±2.4 49.8±8.1
Sex (M/F) 19/10 15/15 10/5 2/8
Baseline serum creatinine (mg per 100 ml) 1.3±0.1 0.9±0.1 2.4±0.3 0.9±0.1
Peak serum creatinine (mg per 100 ml) 4.3±0.4
Serum creatinine at time of urine collection (mg per 100 ml) 3.2±0.2
AKI, acute kidney injury; CKD, chronic kidney disease; UTI, urinary tract infection.
Values are means (±s.e.).
Table 2 | Comparison of various urinary biomarker levels in cross-sectional study
Group (n) Normalized KIM-1 (ng mg1 Ucr) Normalized NAG (U mg1 Ucr) Normalized MMP-9 (ng mg1 Ucr)
AKI (n=29) 3.3 (2.1–5.5)*, ^ 53.6 (20.0–93.5)*, ** 3.9 (0.2–14.9)*
Control (n=45) 0.1 (0.1–0.2) 2.7 (2.3–3.8) 0.0 (0.0–0.3)
Normal (n=30) 0.1 (0.0–0.2) 2.3 (1.9–3.4) 0.0 (0.0–0.7)
CKD (n=15) 0.1 (0.1–0.4) 4.7 (2.4–7.0) 0.0 (0.0–1.3)
UTI (n=10) 0.4 (0.2–2.0) 4.1 (2.2–11.4) 66.9 (11.3–203.3)*, ^^
AKI, acute kidney injury; CKD, chronic kidney disease; KIM-1, kidney injury molecule-1; MMP-9, matrix metalloproteinase-9; NAG, N-acetyl-b-D-glucosaminidase; Ucr, urine
creatinine; UTI, urinary tract infection.
Values are medians (95% CI for median).
*Po0.001 vs control; **Po0.001 vs UTI; ^P=0.002 vs UTI; ^^Po0.001 vs AKI.
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differences were noted between patients with and without
AKI with respect to age, sex, and race. CPB time was
significantly longer in patients with AKI (Po0.001). The
increases in serum creatinine on postoperative days were
statistically significantly different from the baseline and non-
AKI groups (Po0.05).
Quantitation of serial urinary MMP-9, NAG, and KIM-1
proteins. Comparisons of median and mean normalized
biomarker levels among patients with and without AKI in the
case–control study are shown in Table 4 and Figure 3,
respectively. Urinary NAG and KIM-1 were higher among
patients with AKI at multiple time points after CPB. Urinary
KIM-1 increased at 6–12 h after CPB and remained
significantly elevated up to 48 h after CPB. Urinary NAG
increased within 6 h and remained elevated up to 48 h after
CPB. Urinary MMP-9 was not elevated in patients with or
without AKI, and was not a sensitive AKI biomarker in the
case–control study.
ROC analysis of urinary MMP-9, NAG, KIM-1, and combination
of NAG and KIM-1 as early biomarkers for detection of AKI. The
performance of MMP-9, NAG, and KIM-1 in diagnosing AKI
is illustrated in Table 5. At 12, 24, and 36 h after CPB, the
AUCs for the diagnosis of AKI using KIM-1 were 0.83, 0.78,
and 0.84; the AUCs for MMP-9 were 0.50, 0.53, and 0.53; the
AUCs for NAG were 0.69, 0.70, and 0.71; and the AUCs for
combination of NAG and KIM-1 were 0.83, 0.79, and 0.85
(Table 5). Table 6 demonstrates the sensitivity; specificity;
and positive and negative likelihood ratio at 6, 12, and 24 h
after cardiopulmonary bypass for diagnosis of AKI. MMP-9
was excluded in combination of biomarkers because it was
not elevated in patients with or without AKI. The
performance difference between KIM-1 and NAG by AUC
for diagnosis of AKI was not statistically significantly
different. There was no added value for combining two
biomarkers for detection of AKI in our case–control study.
DISCUSSION
The traditional laboratory approach for detection of renal
disease does not allow for early detection of acute renal
injury. Damage to renal tubules can be insufficient to result
in a change in a parameter of kidney function such as serum
creatinine. In addition, in cases of more extensive tubular
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Figure 1 | Comparison of various urinary biomarkers in cross-
sectional study. Combined box and whisker and dot plot of
normalized urinary MMP-9, NAG, and KIM-1 levels is shown among
control (non-AKI), AKI, and UTI groups. AKI, acute kidney injury; UTI,
urinary tract infection.
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Figure 2 | ROC analysis for normalized urinary biomarkers in
cross-sectional study. ROC curves of normalized MMP-9, NAG, and
KIM-1 as a single test and in combination were plotted. The greater
the displacement above and to the left of the line identified, the
greater the likelihood that raised values of the test will identify AKI.
Table 3 | Patient’s characteristic and clinical outcome in
case–control study
AKI (n=20) Non-AKI (n=20)
Age (years) 2.0±1.2 4.4±1.3
Sex (M/F) 13/7 11/9
Serum creatinine (mg per 100 ml)
Baseline (Pre-Op) 0.40±0.04 0.45±0.04
Post-Op (immediately) 0.45±0.05 0.42±0.04
Post-Op day 1 0.59±0.08^, ^^ 0.41±0.04
Post-Op day 2 0.79±0.08*, ** 0.41±0.04
Post-Op day 3 0.65±0.08^, ^^ 0.42±0.06
Cardiopulmonary bypass time (min) 179.0±13.6* 74.5±7.5
Duration of AKI (days) 2.8±0.4 NA
Renal replacement therapy None NA
AKI, acute kidney injury; NA, not available.
Values are means (±s.e.).
*Po0.001 vs non-AKI; ^Po0.05 vs non-AKI.
**Po0.001 vs baseline; ^^Po0.05 vs baseline.
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injury, there is a lag in time between the injury and an
increase in serum creatinine. Sensitive biologic markers of
renal tubular injury are needed in order to detect early kidney
injury. In this study, we demonstrate that (1) urinary MMP-
9, NAG, and KIM-1 can be detected in AKI, and that the
concentration of each marker is significantly higher in urine
samples from patients with AKI compared with urine
samples from patients with chronic kidney disease (CKD)
and normal controls in cross-sectional study; (2) MMP-9 is
associated with AKI but does not differentiate patients with
AKI from those with UTI; (3) urinary NAG and KIM-1 are
elevated well before an increase in serum creatinine in a
prospective case–control study in children undergoing CPB;
and (4) we cannot conclude whether combining biomarkers
enhances diagnostic performance for detection of AKI in the
prospective case–control study.
There have been over 16 definitions used for the diagnosis
of acute renal failure in previously published studies, with
most of them based on serum creatinine values. Recently the
Acute Kidney Injury Network has supported the use of the
term ‘acute kidney injury’ to reflect the broad spectrum of
acute kidney disease, including conditions that do not progress
to ‘failure’.17 Nevertheless, in the absence of a more widely
accepted biomarker for injury, serum creatinine continues
to be used. The change in serum creatinine, however, does
not discriminate the time and type of renal insult or the site
and extent of glomerular or tubular injury. Levels are relatively
insensitive to small changes in GFR and may lag behind
changes in GFR by several days. Therefore, it is a challenge to
detect acute tubular injury in a timely manner so that
intervention can be initiated. Recently, several biomarkers have
been explored for the early diagnosis of AKI, including
neutrophil gelatinase-associated lipocalin (NGAL), inter-
leukin-18, cystatin C, and KIM-1.2 None of these markers,
however, have been systematically evaluated in various clinical
settings of AKI. In this study, we demonstrated that urinary
MMP-9, NAG, and KIM-1 are useful biomarkers for the
identification of established AKI in a cross-sectional study of
patients with clinical and laboratory evidence for AKI. Then
we determined the temporal expression pattern of urinary
MMP-9, NAG, and KIM-1 from the onset of AKI in children
undergoing open-heart surgery. Urinary NAG and KIM-1
increased in the urine before an increase in serum creatinine.
In a prospective study in children, 15 out of 20 AKI patients’
serum creatinine returned to baseline by 5 days after cardio-
pulmonary bypass. Since there was no pathologic evaluation of
the kidney, we cannot relate the biomarkers to injury directly,
but, given the mean increase of creatinine, the AKI suffered
was likely a result of mild to moderate tubular injury.
The heterogeneity of AKI suggests that more than one
marker may be necessary to obtain sufficient sensitivity and
specificity for AKI screening. Analysis of multiple biomarkers
may optimize early detection of AKI as in the case of prostate
Table 4 | Comparison of various urinary marker levels in patients with AKI and non-AKI
Post-Op
Pre-Op 2 h 6 h 12 h 24 h 36 h 48 h
Normalized value
KIM-1 (ng mg1 Ucr) * * * *
AKI 0.2 (0.0–1.2) 0.6 (0.0–2.3) 0.7 (0.2–2.7) 3.6 (1.8–18.0) 4.6 (1.2–14.9) 4.0 (1.9–14.5) 4.7 (3.2–10.8)
Non-AKI 0.4 (0.0–1.9) 1.1 (0.0–3.9) 1.4 (0.2–2.6) 0.4 (0.0–1.6) 0.5 (0.0–1.6) 0.6 (0.0–2.3) 0.9 (0.1–3.1)
NAG (U mg1 Ucr) ** ** **
AKI 17.6 (5.5–52.9) 21.1 (8.6–54.8) 32.0 (10.0–70.9) 78.1 (46.7–255.2) 74.1 (47.2–241.8) 79.1 (53.5–186.9) 80.9 (46.3–128.5)
Non-AKI 28.6 (15.0–59.5) 32.1 (18.3–64.6) 31.9 (21.3–122.0) 39.7 (22.7–117.0) 38.6 (19.3–71.0) 38.1 (15.0–88.9) 44.8 (14.6–87.7)
MMP-9
(ng mg1 Ucr)
AKI ND ND ND ND ND ND ND
Non-AKI ND ND ND ND ND ND ND
AKI, acute kidney injury; ND, non-detectable; Ucr, urine creatinine.
Values are medians (95% CI for median).
*Po0.005 vs non-AKI; **Po0.05 vs non-AKI.
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Figure 3 | Pattern of urinary biomarker expression in case–control
study. Graphs showing mean normalized urine KIM-1, NAG, and
MMP-9 concentrations at multiple time points after cardiopulmonary
bypass. Error bars are s.e.
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cancer detection.18 The main challenge is how to combine
multiple biomarkers for clinical use. A naive approach to
combining multiple biomarkers is to call a result positive if
either one or both biomarkers are positive. Such an
approach, however, can be inefficient and increase sensitivity
at the expense of specificity, or vice versa. In this study, we
used a linear combination that maximized the area under
ROC for detection of AKI. The usefulness of this approach
remains to be validated in future studies.
We recognize that normalization of urinary MMP-9, NAG,
and KIM-1 concentrations to urine creatinine concentration
is less than ideal for a number of reasons including the non-
steady state of creatinine balance in patients with AKI. We
analyzed our data using both absolute and normalized values
in our study and found the results did not markedly differ.
There are a number of limitations to our observational
study. The population studied is not representative of the
global group of patients with AKI. The study is based on two
different populations, with different characteristics. The
cross-section study includes the important group of AKI
patients who suffer ischemic events from either sepsis
or cardiovascular events, which are the major causes of
Table 5 | AUCs for urinary biomarkers at various time points in case–control study
Time after cardiopulmonary bypass
2 h 6 h 12 h 24 h 36 h 48 h
Normalized urinary biomarkers
KIM-1 0.57 0.52 0.83 0.78 0.84 0.81
95% CI (0.50–0.73) (0.50–0.71) (0.67–0.96) (0.61–0.92) (0.69–0.96) (0.65–0.94)
NAG 0.65 0.58 0.69 0.70 0.71 0.66
95% CI (0.51–0.73) (0.50–0.76) (0.52–0.85) (0.54–0.87) (0.54–0.87) (0.51–0.84)
MMP-9 0.55 0.51 0.50 0.53 0.53 0.52
95% CI (0.50–0.69) (0.50–0.63) (0.50–0.62) (0.50–0.61) (0.50–0.63) (0.50–0.63)
Combined (NAG, KIM-1) 0.66 0.61 0.83 0.79 0.85 0.81
95% CI (0.52–0.83) (0.50–0.80) (0.69–0.96) (0.62–0.93) (0.69–0.96) (0.68–0.94)
CI, confidence interval; KIM-1, kidney injury molecule-1; MMP-9, matrix metalloproteinase-9; NAG, N-acetyl-b-D-glucosaminidase.
Table 6 | Performance of urinary KIM-1 and NAG for diagnosis of AKI at various time points in case–control study
Sensitivity Specificity
Positive likelihood
ratio
Negative likelihood
ratio
Urinary KIM-1 at 6 h
42.0 ng mg1 Ucr 65 42 1.12 0.83
47.0 ng mg1 Ucr 85 21 1.08 0.71
418.0 ng mg1 Ucr 90 16 1.07 0.63
Urinary KIM-1 at 12 h
42.0 ng mg1 Ucr 74 90 7.37 0.29
47.0 ng mg1 Ucr 32 90 3.16 0.76
418.0 ng mg1 Ucr 21 90 2.11 0.88
Urinary KIM-1 at 24 h
42.0 ng mg1 Ucr 65 80 3.25 0.44
47.0 ng mg1 Ucr 35 90 3.50 0.72
418.0 ng mg1 Ucr 20 90 2.00 0.89
Urinary NAG at 6 h
410.0 U mg1 Ucr 25 84 1.58 0.89
425.0 U mg1 Ucr 50 63 1.36 0.79
440.0 U mg1 Ucr 55 37 0.87 1.22
Urinary NAG at 12 h
410.0 U mg1 Ucr 100 10 1.11 0.00
425.0 U mg1 Ucr 100 30 1.43 0.00
440.0 U mg1 Ucr 84 55 1.87 0.29
Urinary NAG at 24 h
410.0 U mg1 Ucr 95 20 1.19 0.25
425.0 U mg1 Ucr 85 25 1.13 0.60
440.0 U mg1 Ucr 80 55 1.78 0.36
AKI, acute kidney injury; KIM-1, kidney injury molecule-1; NAG, N-acetyl-b-D-glucosaminidase; Ucr, urine creatinine.
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hospital-acquired AKI.19 The prospective case–control group
was restricted to children undergoing open-heart surgery. We
excluded prerenal azotemia, diagnosed by clinical criteria, in
the cross-sectional study, but it is possible that there might
have been cases of prerenal etiologies in the case–control
study, given the rapid reversibility of serum creatinine to
baseline in AKI group. We did not find that a combination of
urinary biomarkers enhances diagnostic performance of AKI
in our case–control study, perhaps due to the small sample
size. There is currently very limited data available regarding
temporal expression patterns of various urinary biomarkers,
including NGAL, KIM-1. interleukin-18, MMP-9, and
cystatin C, for various clinical settings of AKI from the onset
of renal insult. The usefulness of combining multiple
biomarkers remains to be validated in further studies. In a
follow-up study involving a larger number of adult patients,
we are currently evaluating whether a panel of urinary
biomarkers enhances the detection of AKI.
This study utilized samples from all of the AKI cases and
less than half of the non-AKI cases from a prospective study
in children undergoing cardiopulmonary bypass where AKI
was defined as an increase of 50% in serum creatinine. It is
not possible to determine if any of these patients had prerenal
azotemia. In that study, urinary NGAL was measured and
found to have an AUC–ROC of 0.99 at 2 h and 1.00 at 4 h
following CPB;15 a subsequent study using all of the AKI
cases and under half of the non-AKI cases showed urinary
interleukin-18 to have an AUC–ROC of 0.61 at 4 h, 0.75 at
12 h, and 0.73 at 24 h following CPB.20 In this study, urinary
KIM-1 had an AUC-ROC of 0.57 at 2 h, 0.83 at 12 h, and 0.78
at 24 h. Comparisons among the three biomarkers (NGAL
from the original study and interleukin-18 and KIM-1 at later
dates using frozen samples), however, should be made with
caution for a variety of reasons. The cohorts were all children
with a small sample size. Patients with CKD were excluded
from the cohort. There were no patients who required
dialysis or died. The heterogeneity of AKI was not well
addressed. In addition, the urine samples were thawed and
refrozen two times before this study and were frozen for
about 2 years at 801C. We do not know the influence of
prolonged duration of storage at 801C and number of
freeze–thaw cycles on stability of various urinary biomarkers
at the present time. Our unpublished data indicated that
urinary KIM-1 remained stable after over 1 year of storage at
801C without repeat freeze and thaw cycles. It is possible
that the poor performance of urinary MMP-9 in the
case–control study may be explained by instability of MMP-
9 during prolonged freezing and, thus, further study is
necessary to determine its utility as AKI biomarker.
In conclusion, we have demonstrated that biomarkers may
improve the diagnosis of renal proximal tubule injury and may
result in early detection of AKI. Larger prospective studies are
necessary to validate the temporal expression pattern of various
urinary biomarkers for early detection of AKI, how to combine
multiple biomarkers for early detection of AKI, and how this
temporal course relates to the onset, severity, and outcome of AKI.
MATERIALS AND METHODS
Patient selection and urine collections
Cross-sectional study. In order to identify biomarkers that are
sensitive and specific for the diagnosis of established AKI, 29
patients with various causes of AKI were selected from patients seen
for renal consultation at Brigham and Women’s Hospital (19 males,
10 females; mean: 59 years) between November 2004 and March
2005. In this study, all patients with AKI had a 50% or greater
increase in serum creatinine from baseline and muddy-brown
granular or granular casts in urine sediments on microscopic
examination. An additional 15 patients with various CKDs were
selected from the renal clinic at Brigham and Women’s Hospital
(10 males, five females; mean: 69.2 years). Patients were considered
to have CKD if (1) they had a documented renal disease, which
was diagnosed by renal biopsy and/or on clinical grounds and (2)
the Scr remained relatively stable (±0.5 mg per 100 ml) for at least
6 months. All patients in this group had stage 3 to 5 CKD as
estimated by the Modification of Diet in Renal Disease study
equation.21 CKD etiologies represented in this study include focal
segmental glomerulosclerosis, hypertensive nephrosclerosis, renal
artery stenosis, diabetic nephropathy, and lupus nephritis. Urine
samples were also collected from 30 healthy subjects without known
renal disease with bland urine sediments and from 10 patients with
UTI without evidence of previous renal disease or AKI. All 10 UTI
patients had a positive leukocyturia and urine culture with greater
than 105 colonies. Relevant clinical information was obtained from
the review of patients’ records. Spot urine samples were collected at
the time of renal consult or outpatient clinic visit.
Case–control study. In order to study the expression pattern of
biomarkers before the development of AKI, we analyzed urine
samples that were collected prospectively in patients who were
admitted to Cincinnati Children’s Hospital for surgical correction of
congenital heart disease between January 2004 and November
2004.15 Exclusion criteria included CKD, diabetes mellitus, peri-
pheral vascular disease, and use of nephrotoxic drugs before or
during the study period. Urine samples were collected before surgery
and every 2 h for the first 12 h and then once every 12 h. Serum
creatinine was measured at baseline, routinely monitored at least
twice a day in the immediate postoperative period, and at least daily
after postoperative day 3. Postoperative AKI was defined as a 50% or
greater increase in serum creatinine from baseline. A total of 280
urine samples were collected from all of the 20 pateints with AKI
and randomly selected 20 patients without AKI. Serial urinary
MMP-9, NAG, and KIM-1 levels were measured at the various time
points in this study. Laboratory personal (A Johnson) was blinded
to AKI and non-AKI status.
The institutional review boards of Brigham and Women’s
Hospital and the Cincinnati Children’s Hospital Medical Center
approved the study.
Urine samples
In the cross-sectional study, urine samples were centrifuged to remove
cellular components and debris and the supernatant was stored at801C.
All urine samples were analyzed by urinary dipstick before centrifugation
(Multistix 8 SG; Bayer Corporation, Tarrytown, NY, USA) and by
microscopic examination by one of the authors (WK Han) (using
Olympus microscope). Urine samples in the case–control study were
centrifuged at 2000 g for 5 min and the supernatants were stored at
801C. The samples were thawed and refrozen two times before this
study. The time between initial urine collection and assay at Brigham and
Women’s Hospital was about 2 years.
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Measurement of urinary MMP-9, NAG, and KIM-1
Urinary soluble KIM-1 protein was quantified by a modified enzyme-
linked immunosorbent assay system as previously described.4
Briefly, the wells of an enzyme-linked immunosorbent assay plate
(MaxiSorp; Nunc, Naperville, IL, USA) were coated with anti-KIM-1
polyclonal antibody (overnight incubation at 41C with 200ml of
antibody at 1.0mg ml1 in 50 mM carbonate solution). The wells were
blocked with a bovine serum albumin solution (1% in phosphate-
buffered saline) and were washed four times with PBST (phosphate-
buffered saline with 0.05% Tween 20). Urine samples (100 ml)
were then added to each well at room temperature for 3 h. After
four washes with PBST, biotinylated anti-KIM-1 monoclonal anti-
body (AWE-2) was added, followed by horseradish peroxidase-
conjugated streptavidin and tetramethylbenzidine as substrate. Total
urine MMP-9 concentration was measured using a commercially
available enzyme-linked immunosorbent assay kit (Quantikine; R&D
systems, Minneapolis, MN, USA). NAG was measured by colori-
metric assay by using a commercially available kit (Roche Applied
Science, Indianapolis, IN, USA). The measured values were normal-
ized to the urinary creatinine concentration. The inter-assay and
intra-assay coefficients of variation for MMP-9, NAG, and KIM-1
were less than 10%.
Serum and urinary creatinine determination
Serum and urine creatinine concentrations were measured by
the Jaffe´ assay using Roche/Hitachi 917 and 911 systems (Roche
Diagnostics, Indianapolis, IN, USA), respectively.
Statistical analysis
Continuous variables were compared using the Student’s t-test or the
non-parametric Mann–Whitney U-test, as appropriate. For analysis of
single biomarkers, ROC curves were drawn and the AUCs calculated
and compared using the method of Hanley and McNeil22 for the cross-
sectional data and comparison for a single time point for the
case–control data. Two-tailed P-values less than 0.05 were considered
statistically significant. For joint analysis of multiple biomarkers, the
linear combination that maximized the area under the ROC curve was
found.23 For the cross-sectional study, the formula for multiple
biomarkers was [normalized KIM-1 concentration]þ 0.18[normalized
NAG concentration]þ 0.1[MMP-9 concentration]. For the case–con-
trol study, the formula was [normalized KIM-1 concentration]þ
0.25[normalized NAG concentration]. Bootstrap percentile confidence
intervals were calculated using 2000 resamples. Statistical analyses were
performed using SAS Version 9.1 (SAS Institute, Cary, NC, USA),
MedCalc Version 9.3.1 (MedCalc Inc., Mariakerke, Belgium), and R
version 2.1.1 (http://www.r-project.org).
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